GUT RESPONSES
As a reminder, this is not for CME/CE credit, but rather informative presentations for you and your staff to view to learn more about IBS-D and VIBERZI.
Kimberly Orleck, PA-C
Faculty, PA Program, Emory University;
Director, Advanced Practice Providers,
Atlanta Gastroenterology Associates
United Digestive
Atlanta, GA
Jonathan Rosenberg, MD
Clinical Assistant Professor,
Department of Medicine,
NYU Grossman School of Medicine
New York, NY
Arin Newman, MD
Gastroenterology, Internal Medicine
Physicians Group of South Florida, P.A.
Miami, FL
Kimberly Orleck
PA-C
Faculty, PA Program, Emory University;
Director, Advanced Practice Providers,
Atlanta Gastroenterology Associates
United Digestive
Atlanta, GA
Arin Newman
MD
Gastroenterology, Internal Medicine
Physicians Group of South Florida, P.A.
Miami, FL
Jonathan
Rosenberg
MD
Clinical Assistant Professor,
Department of Medicine,
NYU Grossman School of Medicine
New York, NY
I am concerned about prescribing VIBERZI because it is scheduled.
In this episode, Kimberly Orleck discusses VIBERZI’s scheduled status, focusing on its low abuse potential, minimal risk of dependence, and positive trial outcomes, while providing a clear perspective for managing IBS-D. vs what is there now.
VIEW TRANSCRIPT >
I am concerned about prescribing VIBERZI because it is scheduled.
I’m concerned about the safety of VIBERZI.
None of my patients with IBS-D have a gallbladder.
I’m happy with my current IBS-D treatment options.
I don’t see a lot of IBS-D patients.
I typically use VIBERZI for the more severe patient.
I’m concerned about the safety of VIBERZI.
In this episode, Kimberly Orleck discusses the safety of VIBERZI, as well as common concerns about treating IBS-D in patients with certain contraindications related to pancreatitis.
VIEW TRANSCRIPT >
I am concerned about prescribing VIBERZI because it is scheduled.
In this episode, Kimberly Orleck discusses VIBERZI’s scheduled status, focusing on its low abuse potential, minimal risk of dependence, and positive trial outcomes, while providing a clear perspective for managing IBS-D. vs what is there now.
VIEW TRANSCRIPT >
None of my patients with IBS-D have a gallbladder.
In this episode, Dr. Rosenberg tackles the issue of gallbladder surgery in patients with IBS-D, and discusses his confidence in the safety of VIBERZI in patients with intact gallbladders.
VIEW TRANSCRIPT >
I’m happy with my current IBS-D treatment options.
In this episode, Dr. Rosenberg touches on the efficacy of VIBERZI, and how it stands out as a good treatment option for IBS-D, citing its proven success with his patients.
VIEW TRANSCRIPT >
I don’t see a lot of IBS-D patients.
In this episode, Dr. Newman examines common IBS-D symptoms and how to use ROME criteria to make an accurate positive diagnosis. Asking patients the right questions about IBS-D can help patients get the treatment they need.
VIEW TRANSCRIPT >
I typically use VIBERZI for the more severe patient.
In this episode, Dr. Newman discusses the range of IBS-D severity and the main symptoms VIBERZI targets.
VIEW TRANSCRIPT >
VIBERZI SAMPLES
Free samples available for your patients!
ORDER HERE >Not available where prohibited by law.
VIBERZI® (eluxadoline) CIV is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
VIBERZI is contraindicated in patients:
- Without a gallbladder.
- With known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction; a history of pancreatitis; or structural diseases of the pancreas.
- With alcoholism, alcohol abuse, alcohol addiction, or who drink more than 3 alcoholic beverages per day.
- With a known hypersensitivity reaction to VIBERZI.
- With severe hepatic impairment.
- With a history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction.
- Pancreatitis, with or without sphincter of Oddi spasm, has been reported in patients taking either the 75 mg or 100 mg dosage of VIBERZI, including serious cases resulting in hospitalization, primarily in patients without a gallbladder. Fatal cases have also been reported in patients without a gallbladder. VIBERZI is contraindicated in patients without a gallbladder. Most of the reported cases of serious pancreatitis occurred within a week of starting treatment with VIBERZI and some patients developed symptoms after one to two doses.
- In patients with a gallbladder, evaluate a patient’s alcohol intake prior to starting VIBERZI. Instruct patients to avoid chronic or acute excessive alcohol use while taking VIBERZI. Monitor for new or worsening abdominal pain that may radiate to the back or shoulder, with or without nausea and vomiting. Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of pancreatitis such as acute abdominal or epigastric pain radiating to the back or shoulder associated with elevations of pancreatic enzymes with or without nausea and vomiting.
- There is a risk of sphincter of Oddi spasm, resulting in pancreatitis or hepatic enzyme elevation associated with acute abdominal pain (eg, biliary-type pain) in patients taking VIBERZI. Serious adverse reactions of sphincter of Oddi spasm with or without pancreatitis resulting in hospitalization have been reported, primarily in patients without a gallbladder. Cases of serious sphincter of Oddi spasm occurred within a week of starting treatment with VIBERZI and some patients developed symptoms after one to two doses.
- Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of sphincter of Oddi spasm such as acute worsening of abdominal pain that may radiate to the back or shoulder with or without nausea and vomiting, associated with elevations of pancreatic enzymes or liver transaminases. Do not restart VIBERZI in patients who developed biliary duct obstruction while taking VIBERZI.
- In postmarketing experience, serious hypersensitivity reactions (including anaphylaxis) have been reported following VIBERZI administration. Some of these reactions occurred after the first one or two doses of VIBERZI.
- Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of a hypersensitivity reaction.
- Constipation, sometimes requiring hospitalization, has been reported following VIBERZI administration. In postmarketing experience, severe cases with development of intestinal obstruction, intestinal perforation, and fecal impaction, requiring intervention, have also been reported. Instruct patients to stop VIBERZI and immediately contact their healthcare provider if they experience severe constipation. Avoid use with other drugs that may cause constipation.
The most commonly reported adverse reactions (incidence >5% and greater than placebo) were constipation, nausea, and abdominal pain.
Please see full Prescribing Information.
